Lipocine
LPCN
28 hedge funds and large institutions have $1.64M invested in Lipocine in 2020 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 7 closing their positions.
0.46% less ownership
Funds ownership: 0.9% → 0.45% (-0.46%)
13% less funds holding
Funds holding: 32 → 28 (-4)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
23% less capital invested
Capital invested by funds: $2.12M → $1.64M (-$481K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$126K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$69.2K |
| 3 |
FPCG
Fort Pitt Capital Group
Pittsburgh,
Pennsylvania
|
+$24.1K |
| 4 |
Mercer Global Advisors
Denver,
Colorado
|
+$23.3K |
| 5 |
BlackRock
New York
|
+$14.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$757K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$142K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$105K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$22K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$17K |
LPCN Hedge Fund Activity: Q1 2020 in Review
28 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2020, worth a combined $1.64M — down 23% from $2.12M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of LPCN and 6 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Ameriprise, adding an estimated $126K. The largest seller was Renaissance Technologies, cutting an estimated $757K.
- 28 institutional investors held Lipocine (LPCN) as of Q1 2020, down from 32 in Q4 2019.
- Funds reported $1.64M of Lipocine stock for Q1 2020, down 23% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q1 2020 and 7 closed out, a net change of -1 holder.
- The largest Lipocine buyer in Q1 2020 was Ameriprise, an estimated $126K added.
- The largest Lipocine seller in Q1 2020 was Renaissance Technologies, an estimated $757K sold.
Based on aggregated 13F filings for Q1 2020.